Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,395 questions in 172 reviews · Gut
current versionsNo studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tofacitinib vs placebo Withdrawals due to adverse events (5 mg/10 mg) · participants with quiescent ulcerative colitis Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis (2020) · Cochrane | RR 0.5 [0.33, 0.77] | 1 study · 592 participants | Moderate |
Adalimumab vs placebo Failure to maintain clinical remission · People with quiescent Crohn's disease Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | RR 0.7 [0.64, 0.77] | 3 studies · 683 participants | High |
Adalimumab vs active comparator Adverse events · People with quiescent Crohn's disease (ileocolic resection) Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Adalimumab vs active comparator Serious adverse events · People with quiescent Crohn's disease (ileocolic resection) Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Adalimumab vs active comparator Withdrawal due to adverse events · People with quiescent Crohn's disease (ileocolic resection) Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Adalimumab vs active comparator Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure · People with quiescent Crohn's disease (ileocolic resection) Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Adalimumab vs placebo Failure to maintain clinical remission · People with quiescent Crohn's disease Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | RR 0.66 [0.52, 0.83] | 2 studies · 554 participants | Moderate |
Adalimumab vs placebo Failure to maintain endoscopic remission · People with quiescent Crohn's disease Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | RR 0.74 [0.63, 0.87] | 1 study · 129 participants | Moderate |
Adalimumab vs placebo Adverse events · People with quiescent Crohn's disease Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | RR 1.01 [0.94, 1.09] | 4 studies · 1012 participants | High |
Adalimumab vs placebo Serious adverse events · People with quiescent Crohn's disease Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | RR 0.56 [0.39, 0.8] | 4 studies · 1012 participants | Moderate |
Adalimumab vs placebo Withdrawals due to adverse events · People with quiescent Crohn's disease Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | RR 0.59 [0.38, 0.91] | 4 studies · 1012 participants | Moderate |
Adalimumab vs placebo Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure · People with quiescent Crohn's disease Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | RR 0.76 [0.68, 0.85] | 2 studies · 302 participants | Moderate |
Adalimumab vs active comparator Failure to maintain clinical remission · People with quiescent Crohn's disease (ileocolic resection) Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Adalimumab vs active comparator Failure to maintain endoscopic remission · People with quiescent Crohn's disease (ileocolic resection) Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | RR 0.11 [0.02, 0.75] | 1 study · 51 participants | Very low |
Risk of postoperative infectious complications: corticosteroids vs control Overall infectious complications within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.4 [1.23, 1.6] | 41 studies · 41 participants | Very low |
Risk of postoperative infectious complications: 5‐ASA vs control Incisional infections and wound dehiscence within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 0.53 [0.3, 0.95] | 1 study · 1 participants | Ungraded |
Risk of postoperative infectious complications: 5‐ASA vs control Intra‐abdominal infectious complications within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 0.77 [0.45, 1.33] | 3 studies · 3 participants | Very low |
Risk of postoperative infectious complications: 5‐ASA vs control Extra‐abdominal infections within 30 days of surgery 1 · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk of postoperative infectious complications: immunomodulators vs control Overall infectious complications within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.11 [0.97, 1.26] | 31 studies · 31 participants | Very low |
Risk of postoperative infectious complications: immunomodulators vs control Overall infectious complications within 30 days of surgery (Adjusted Analysis) · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.29 [0.95, 1.76] | 9 studies · 9 participants | Low |
Risk of postoperative infectious complications: immunomodulators vs control Overall infectious complications within 30 days of surgery (Unadjusted Analysis) · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.07 [0.93, 1.24] | 22 studies · 22 participants | Very low |
Risk of postoperative infectious complications: immunomodulators vs control Incisional infections and wound dehiscence within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.35 [0.96, 1.89] | 11 studies · 11 participants | Very low |
Risk of postoperative infectious complications: immunomodulators vs control Intra‐abdominal infectious complications within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 0.86 [0.66, 1.12] | 20 studies · 20 participants | Very low |
Risk of postoperative infectious complications: immunomodulators vs control Extra‐abdominal infections within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.17 [0.8, 1.71] | 4 studies · 4 participants | Very low |
Risk of postoperative infectious complications: anti‐TNF agents vs control Overall infectious complications within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.27 [1.09, 1.47] | 54 studies · 54 participants | Very low |
Risk of postoperative infectious complications: corticosteroids vs control Overall infectious complications within 30 days of surgery (Adjusted Analysis) · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.7 [1.38, 2.09] | 17 studies · 17 participants | Low |
Risk of postoperative infectious complications: anti‐TNF agents vs control Overall infectious complications within 30 days of surgery (Adjusted Analysis) · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.6 [1.2, 2.13] | 17 studies · 17 participants | Very low |
Risk of postoperative infectious complications: anti‐TNF agents vs control Overall infectious complications within 30 days of surgery (Unadjusted Analysis) · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.14 [0.96, 1.36] | 37 studies · 37 participants | Very low |
Risk of postoperative infectious complications: anti‐TNF agents vs control Incisional infections and wound dehiscence within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.18 [0.83, 1.68] | 24 studies · 24 participants | Very low |
Risk of postoperative infectious complications: anti‐TNF agents vs control Intra‐abdominal infectious complications within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.38 [1.04, 1.82] | 39 studies · 39 participants | Very low |
Risk of postoperative infectious complications: anti‐TNF agents vs control Extra‐abdominal infections within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.34 [0.96, 1.87] | 13 studies · 13 participants | Very low |
Risk of postoperative infectious complications: anti‐integrin agents vs control Overall infectious complications within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.11 [0.76, 1.62] | 9 studies · 9 participants | Very low |
Risk of postoperative infectious complications: anti‐integrin agents vs control Overall infectious complications within 30 days of surgery (Adjusted Analysis) · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.04 [0.79, 1.36] | 2 studies · 2 participants | Low |
Risk of postoperative infectious complications: anti‐integrin agents vs control Overall infectious complications within 30 days of surgery (Unadjusted Analysis) · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.06 [0.54, 2.1] | 7 studies · 7 participants | Very low |
Risk of postoperative infectious complications: anti‐integrin agents vs control Incisional infections and wound dehiscence within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.64 [0.77, 3.5] | 6 studies · 6 participants | Very low |
Risk of postoperative infectious complications: anti‐integrin agents vs control Intra‐abdominal infectious complications within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 0.4 [0.14, 1.2] | 5 studies · 5 participants | Very low |
Risk of postoperative infectious complications: corticosteroids vs control Overall infectious complications within 30 days of surgery (Unadjusted Analysis) · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.22 [1.03, 1.45] | 24 studies · 24 participants | Very low |
Risk of postoperative infectious complications: anti‐integrin agents vs control Extra‐abdominal infections within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.15 [0.43, 3.08] | 5 studies · 5 participants | Very low |
Risk of postoperative infectious complications: corticosteroids vs control Incisional infections and wound dehiscence within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.41 [0.72, 2.74] | 7 studies · 7 participants | Very low |
Risk of postoperative infectious complications: corticosteroids vs control Intra‐abdominal infectious complications within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.53 [1.28, 1.84] | 28 studies · 28 participants | Very low |
Risk of postoperative infectious complications: corticosteroids vs control Extra‐abdominal infections within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 1.23 [0.97, 1.55] | 4 studies · 4 participants | Very low |
Risk of postoperative infectious complications: 5‐ASA vs control Overall infectious complications within 30 days of surgery · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 0.76 [0.51, 1.14] | 6 studies · 6 participants | Very low |
Risk of postoperative infectious complications: 5‐ASA vs control Overall infectious complications within 30 days of surgery (Adjusted Analysis) · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk of postoperative infectious complications: 5‐ASA vs control Overall infectious complications within 30 days of surgery (Unadjusted Analysis) · inflammatory bowel disease Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease (2020) · Cochrane | OR 0.76 [0.51, 1.14] | 6 studies · 6 participants | Very low |
Ciprofloxacin vs metronidazole Clinical remission · Patients with acute pouchitis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | RR 2.68 [1.13, 6.35] | 1 study · 16 participants | Very low |
Metronidazole vs budesonide enema Adverse events · Patients with acute pouchitis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | RR 2.29 [0.78, 6.73] | 1 study · 26 participants | Very low |
Rifaximin vs placebo Clinical remission · Patients with acute pouchitis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | RR 6.11 [0.33, 111.71] | 1 study · 18 participants | Very low |
Rifaximin vs placebo Clinical improvement · Patients with acute pouchitis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | RR 1.25 [0.34, 4.6] | 1 study · 18 participants | Very low |
Rifaximin vs placebo Maintenance of clinical remission · Patients with acute pouchitis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | no estimate extracted | NR | No studies |
Rifaximin vs placebo No episodes acute pouchitis · Patients with acute pouchitis Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (2019) · Cochrane | no estimate extracted | NR | No studies |